Skip to main content
Top
Published in: Drug Safety 13/2001

01-11-2001 | Leading Article

Methods and Systems to Detect Adverse Drug Reactions in Hospitals

Author: Dr Petra A. Thürmann

Published in: Drug Safety | Issue 13/2001

Login to get access

Abstract

Detection of adverse drug reactions (ADRs) in hospitals offers the chance to detect serious ADRs resulting in hospitalisation and ADRs occurring in hospitalised patients, i.e. patients with high comorbidity and receiving drugs that are administered only in hospitals. The most commonly applied methods involve stimulated spontaneous reporting of doctors and nurses, comprehensive collection by trained specialists and, more recently, computer-assisted approaches using routine data from hospital information systems. The different methods of ADR detection used result in different rates and types of ADRs and, consequently, in different drug classes being responsible for these ADRs. Another factor influencing the results of surveys is the interpretation of the term ADR, where some authors adhere to the strict definition of the World Health Organization and many others include intended and unintended poisoning as well as errors in prescribing and dispensing, thus referring to adverse drug events. Depending on the method used for screening of patients, a high number of possible ADRs and only few definite ADRs are found, or vice versa. These variations have to be taken into account when comparing the results of further analyses performed with these data. ADR rates and incidences in relation to the number of drugs prescribed or patients exposed have been calculated in only a few surveys and projects, and this interesting pharmacoepidemiological approach deserves further study. In addition, the pharmacoeconomic impact ofADRs, either resulting in hospitalisation or prolonging hospital stay, has been estimated using different approaches. However, a common standardised procedure for such calculations has not yet been defined. Although detection of ADRs in hospitals offers the opportunity to detect severe ADRs of newly approved drugs, these ADRs are still discovered by spontaneous reporting systems. The prospects offered by electronic hospital information systems as well as implementation of pharmacoepidemiological approaches increases the possibilities and the value of ADR detection in hospitals.
Literature
2.
go back to reference Hurwitz N, Wade OL. Intensive hospital monitoring of adverse reactions to drugs. BMJ 1969; 1: 536–9PubMedCrossRef Hurwitz N, Wade OL. Intensive hospital monitoring of adverse reactions to drugs. BMJ 1969; 1: 536–9PubMedCrossRef
3.
go back to reference Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA 1998; 279: 1200–7PubMedCrossRef Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA 1998; 279: 1200–7PubMedCrossRef
5.
go back to reference Classen DC, Burke JP, Pestotnik SL, et al. Surveillance for quality assessment: IV. surveillance using a hospital information system. Infect Control Hosp Epidemiol 1991; 12: 239–44PubMedCrossRef Classen DC, Burke JP, Pestotnik SL, et al. Surveillance for quality assessment: IV. surveillance using a hospital information system. Infect Control Hosp Epidemiol 1991; 12: 239–44PubMedCrossRef
6.
go back to reference Muehlberger N, Schneeweiss S, Hasford J. Adverse drug reaction monitoring — cost and benefit considerations part I: frequency of adverse drug reactions causing hospital admission. Pharmacoepidemiol Drug Saf 1997; 6(3 Suppl.): S71–7PubMedCrossRef Muehlberger N, Schneeweiss S, Hasford J. Adverse drug reaction monitoring — cost and benefit considerations part I: frequency of adverse drug reactions causing hospital admission. Pharmacoepidemiol Drug Saf 1997; 6(3 Suppl.): S71–7PubMedCrossRef
7.
go back to reference Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring — cost and benefit considerations part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf 1997; 6(3 Suppl.): S79–90PubMedCrossRef Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring — cost and benefit considerations part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf 1997; 6(3 Suppl.): S79–90PubMedCrossRef
8.
go back to reference Hallas J, Gram LF, Grodum E, et al. Drug related admissions to medical wards: a population based survey. Br J Clin Pharmacol 1992; 33: 61–8PubMedCrossRef Hallas J, Gram LF, Grodum E, et al. Drug related admissions to medical wards: a population based survey. Br J Clin Pharmacol 1992; 33: 61–8PubMedCrossRef
9.
go back to reference Schneeweiss S, Göttler M, Hasford J, et al. First results from an intensified monitoring system to estimate drug-related hospital admissions. Br J Clin Pharmacol. Br J Clin Pharmacol 2001; 52: 196–200 Schneeweiss S, Göttler M, Hasford J, et al. First results from an intensified monitoring system to estimate drug-related hospital admissions. Br J Clin Pharmacol. Br J Clin Pharmacol 2001; 52: 196–200
10.
go back to reference Evans JMM, MacDonald TM. Record-linkage for pharmacovigilance in Scotland. Br J Clin Pharmacol 1999; 47: 105–10PubMedCrossRef Evans JMM, MacDonald TM. Record-linkage for pharmacovigilance in Scotland. Br J Clin Pharmacol 1999; 47: 105–10PubMedCrossRef
11.
go back to reference Currie CJ, MacDonald TM. Use of routine healthcare data in safe and cost-effective drug use. Drug Saf 2000; 22: 97–102PubMedCrossRef Currie CJ, MacDonald TM. Use of routine healthcare data in safe and cost-effective drug use. Drug Saf 2000; 22: 97–102PubMedCrossRef
12.
go back to reference Teweleit S, Kuschel U, Hippius M, et al. Manifestation und Präventionsmöglichkeiten unerwünschter Arzneimittelwirkungen (UAW) in der Pharmakotherapie von Herz-Kreislauferkrankungen. Med Klin 2001; 96: 442–50CrossRef Teweleit S, Kuschel U, Hippius M, et al. Manifestation und Präventionsmöglichkeiten unerwünschter Arzneimittelwirkungen (UAW) in der Pharmakotherapie von Herz-Kreislauferkrankungen. Med Klin 2001; 96: 442–50CrossRef
13.
go back to reference Hayes JL, Evans JMM, Lipworth BP, et al. Potentially hazardous co-prescribing of β-adrenoceptor antagonists and agonists in the community. Br J Gen Pract 1996; 46: 423–5PubMed Hayes JL, Evans JMM, Lipworth BP, et al. Potentially hazardous co-prescribing of β-adrenoceptor antagonists and agonists in the community. Br J Gen Pract 1996; 46: 423–5PubMed
14.
go back to reference Bates DW, Spell N, Cullen DC, et al. The costs of adverse drug events in hospitalized patients. JAMA 1997; 277: 307–11PubMedCrossRef Bates DW, Spell N, Cullen DC, et al. The costs of adverse drug events in hospitalized patients. JAMA 1997; 277: 307–11PubMedCrossRef
15.
go back to reference Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. JAMA 1997; 277: 301–6PubMedCrossRef Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. JAMA 1997; 277: 301–6PubMedCrossRef
16.
go back to reference van den Bemt PMLA, Egberts ACG, Lenderink AW, et al. Adverse drug events in hospitalised patients: a comparison of doctors, nurses and patients as sources of reports. Eur J Clin Pharmacol 1999; 55: 155–8PubMedCrossRef van den Bemt PMLA, Egberts ACG, Lenderink AW, et al. Adverse drug events in hospitalised patients: a comparison of doctors, nurses and patients as sources of reports. Eur J Clin Pharmacol 1999; 55: 155–8PubMedCrossRef
17.
go back to reference Mannesse CK, Derkx FHM, de Ridder MAJ, et al. Adverse drug reactions in elderly patients as contributing factor for hospital admission: cross sectional study. BMJ 1997; 315: 1057–9PubMedCrossRef Mannesse CK, Derkx FHM, de Ridder MAJ, et al. Adverse drug reactions in elderly patients as contributing factor for hospital admission: cross sectional study. BMJ 1997; 315: 1057–9PubMedCrossRef
18.
go back to reference Moore N, Lecointre D, Noblet C, et al. Frequency and cost of serious adverse drug reactions in a department of general medicine.Br J Clin Pharmacol 1998; 45: 301–8PubMedCrossRef Moore N, Lecointre D, Noblet C, et al. Frequency and cost of serious adverse drug reactions in a department of general medicine.Br J Clin Pharmacol 1998; 45: 301–8PubMedCrossRef
19.
go back to reference Martinez-Mir I, Garcia-Lopez M, Palop V, et al. A prospective study of adverse drug reactions as a cause of admission to a pediatric hospital. Br J Clin Pharmacol 1996; 42: 319–24PubMedCrossRef Martinez-Mir I, Garcia-Lopez M, Palop V, et al. A prospective study of adverse drug reactions as a cause of admission to a pediatric hospital. Br J Clin Pharmacol 1996; 42: 319–24PubMedCrossRef
20.
21.
go back to reference Classen DC, Pestotnik SL, Evans RS, et al. Computerized surveillance of adverse drug events in hospital patients. JAMA 1991; 266: 2847–51PubMedCrossRef Classen DC, Pestotnik SL, Evans RS, et al. Computerized surveillance of adverse drug events in hospital patients. JAMA 1991; 266: 2847–51PubMedCrossRef
22.
go back to reference Leape LL, Bates DW, Cullen DC, et al. System analysis of adverse drug events. JAMA 1995; 274: 35–43PubMedCrossRef Leape LL, Bates DW, Cullen DC, et al. System analysis of adverse drug events. JAMA 1995; 274: 35–43PubMedCrossRef
23.
go back to reference Dormann H, Muth-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalisation. Drug Saf 2000; 2: 161–8CrossRef Dormann H, Muth-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalisation. Drug Saf 2000; 2: 161–8CrossRef
24.
go back to reference Azaz-Livshits T, Levy M, Sadan B, et al. Computerized surveillance of adverse drug reactions in hospital: pilot study. Br J Clin Pharmacol 1998; 45: 309–14PubMedCrossRef Azaz-Livshits T, Levy M, Sadan B, et al. Computerized surveillance of adverse drug reactions in hospital: pilot study. Br J Clin Pharmacol 1998; 45: 309–14PubMedCrossRef
25.
go back to reference Leape L, Brennan T, Laird N, et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med 1991; 324: 377–84PubMedCrossRef Leape L, Brennan T, Laird N, et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med 1991; 324: 377–84PubMedCrossRef
26.
go back to reference Tegeder I, Levy M, Muth-Selbach U, et al. Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol 1999; 47: 557–64PubMedCrossRef Tegeder I, Levy M, Muth-Selbach U, et al. Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol 1999; 47: 557–64PubMedCrossRef
27.
go back to reference Lau HS, Florax C, Porsius AJ, et al. The completeness of medication histories in hospital medical records of patients admitted to general internal medicine wards. Br J Clin Pharmacol 2000; 49: 597–603PubMedCrossRef Lau HS, Florax C, Porsius AJ, et al. The completeness of medication histories in hospital medical records of patients admitted to general internal medicine wards. Br J Clin Pharmacol 2000; 49: 597–603PubMedCrossRef
28.
go back to reference Bowman L, Carlstedt BC, Black CD. Incidence of adverse drug reactions in adult medical inpatients. Can J Hosp Pharm 1994; 47: 209–16PubMed Bowman L, Carlstedt BC, Black CD. Incidence of adverse drug reactions in adult medical inpatients. Can J Hosp Pharm 1994; 47: 209–16PubMed
29.
go back to reference Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999; 282: 267–70PubMedCrossRef Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999; 282: 267–70PubMedCrossRef
30.
go back to reference Roughead EE, Gilbert AL, Primrose JG, et al. Drug-related hospital admissions: a review of Australian studies published 1988 — 1996. Med J Aust 1998; 168: 405–8PubMed Roughead EE, Gilbert AL, Primrose JG, et al. Drug-related hospital admissions: a review of Australian studies published 1988 — 1996. Med J Aust 1998; 168: 405–8PubMed
31.
go back to reference Beard K. Adverse drug reactions as a cause of hospital admission in the aged. Drugs Aging 1992; 2: 356–67PubMedCrossRef Beard K. Adverse drug reactions as a cause of hospital admission in the aged. Drugs Aging 1992; 2: 356–67PubMedCrossRef
32.
go back to reference Fattinger K, Roos M, Vergères P, et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000; 49: 158–67PubMedCrossRef Fattinger K, Roos M, Vergères P, et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000; 49: 158–67PubMedCrossRef
33.
go back to reference Thürmann PA, Hompesch BC. Influence of gender on pharmacokinetics and pharmacodynamics of drugs. Int J Clin Pharmacol Ther 1998; 36: 586–90PubMed Thürmann PA, Hompesch BC. Influence of gender on pharmacokinetics and pharmacodynamics of drugs. Int J Clin Pharmacol Ther 1998; 36: 586–90PubMed
34.
go back to reference Imbs JL, Pouyanne P, Haramburu F, et al. Iatrogénie médicamenteuse: estimation de sa prévalence dans les hôpitaux publics français. Thérapie 1999; 54: 21–7PubMed Imbs JL, Pouyanne P, Haramburu F, et al. Iatrogénie médicamenteuse: estimation de sa prévalence dans les hôpitaux publics français. Thérapie 1999; 54: 21–7PubMed
35.
go back to reference Pouyanne P, Haramburu F, Imbs JL, et al., for the French Pharmacovigilance Centres. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. BMJ 2000; 320: 1036PubMedCrossRef Pouyanne P, Haramburu F, Imbs JL, et al., for the French Pharmacovigilance Centres. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. BMJ 2000; 320: 1036PubMedCrossRef
37.
go back to reference Schmitt K, Windecker R, Steffen J, et al. Detection of adverse drug reactions by a computer-based generation of laboratory signals [abstract]. Br J Clin Pharmacol 2000 [Abstracts of CPT 2000]; 87: A331 Schmitt K, Windecker R, Steffen J, et al. Detection of adverse drug reactions by a computer-based generation of laboratory signals [abstract]. Br J Clin Pharmacol 2000 [Abstracts of CPT 2000]; 87: A331
38.
go back to reference World Health Organization. International drug monitoring: the role of the hospital. WHO Tech Rep Ser 1969; No. 425 World Health Organization. International drug monitoring: the role of the hospital. WHO Tech Rep Ser 1969; No. 425
39.
go back to reference Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255–9PubMedCrossRef Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255–9PubMedCrossRef
40.
go back to reference Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. JAMA 1995; 274: 29–34PubMedCrossRef Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. JAMA 1995; 274: 29–34PubMedCrossRef
41.
go back to reference Bergman U, Wiholm BE. Drug-related problems causing admission to a medical clinic. Eur J Clin Pharmacol 1981; 20: 193–200PubMedCrossRef Bergman U, Wiholm BE. Drug-related problems causing admission to a medical clinic. Eur J Clin Pharmacol 1981; 20: 193–200PubMedCrossRef
43.
go back to reference Pirmohamed M, Breckenridge AM, Kitteringham NR, et al. Adverse drug reactions. BMJ 1998; 316: 1295-8 Pirmohamed M, Breckenridge AM, Kitteringham NR, et al. Adverse drug reactions. BMJ 1998; 316: 1295-8
44.
go back to reference Naranjo S, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–45PubMedCrossRef Naranjo S, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–45PubMedCrossRef
45.
go back to reference Netting an important database [editorial]. Lancet 2001; 357: 649 Netting an important database [editorial]. Lancet 2001; 357: 649
46.
go back to reference Hallas J, Harvald B, Worm J, et al. Drug related hospital admissions. Eur J Clin Pharmacol 1993; 45: 199–203PubMedCrossRef Hallas J, Harvald B, Worm J, et al. Drug related hospital admissions. Eur J Clin Pharmacol 1993; 45: 199–203PubMedCrossRef
47.
go back to reference Evans RS, Pestotnik SL, Classen DC, et al. Preventing adverse drug events in hospitalized patients. Ann Pharmacother 1994; 28: 523–7PubMed Evans RS, Pestotnik SL, Classen DC, et al. Preventing adverse drug events in hospitalized patients. Ann Pharmacother 1994; 28: 523–7PubMed
48.
go back to reference Landis NT. ADE rate uncertain, reporting systems inadequate, GAO tells legislators. Am J Health Syst Pharm 2000; 57:515–23PubMed Landis NT. ADE rate uncertain, reporting systems inadequate, GAO tells legislators. Am J Health Syst Pharm 2000; 57:515–23PubMed
49.
go back to reference Wood AJ. Thrombotic thrombocytopenic purpura and clopidogrel — a need for new approaches to drug safety. N Engl J Med 2000; 342: 1824–6PubMedCrossRef Wood AJ. Thrombotic thrombocytopenic purpura and clopidogrel — a need for new approaches to drug safety. N Engl J Med 2000; 342: 1824–6PubMedCrossRef
50.
go back to reference Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342: 1773–7PubMedCrossRef Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342: 1773–7PubMedCrossRef
51.
go back to reference Moore N. The role of the clinical pharmacologist in the management of adverse drug reactions. Drug Saf 2001; 24: 1–7PubMedCrossRef Moore N. The role of the clinical pharmacologist in the management of adverse drug reactions. Drug Saf 2001; 24: 1–7PubMedCrossRef
Metadata
Title
Methods and Systems to Detect Adverse Drug Reactions in Hospitals
Author
Dr Petra A. Thürmann
Publication date
01-11-2001
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 13/2001
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200124130-00003

Other articles of this Issue 13/2001

Drug Safety 13/2001 Go to the issue